Last updated: February 21, 2026
What is the Scope of Patent AU2007279643?
Patent AU2007279643 relates to a pharmaceutical compound purposed for therapeutic use. Its scope encompasses the specific chemical entity, its method of synthesis, pharmaceutical formulations, and its application for particular medical indications. The patent claims primarily focus on a novel compound with a specified chemical structure, along with methods of preparing and using this compound in treatment.
The patent provides protection for both the compound itself and specific formulations. It may also extend to methods of administering the compound to patients for treating targeted conditions. The scope covers:
- Chemical Structure: Defined by a specific molecular formula, including optional substitutions.
- Preparation Methods: Synthesis routes delineated in the description.
- Therapeutic Use: Application in treating diseases or conditions such as cancer, inflammation, or metabolic disorders.
- Formulations: Pharmaceutical compositions that include the compound, such as tablets, capsules, injections, or topical formulations.
The patent's claims are likely divided into independent claims covering the compound and related claims covering specific uses or formulations.
How Broad or Narrow Are the Patent Claims?
The patent claims are drafting-dependent but generally fall into these categories:
1. Compound Claims
- Cover a specific chemical compound with defined properties.
- Typically include a Markush structure allowing for minor variations.
- Claim scope includes salts, stereoisomers, and pharmaceutically acceptable derivatives.
2. Use Claims
- Cover methods of using the compound to treat diseases.
- Often include claims for methods of treatment, administration schedules, or dosage.
3. Formulation Claims
- Cover pharmaceutical compositions containing the compound.
- May encompass delivery systems or specific excipients.
4. Process Claims
- Cover methods of synthesizing the compound.
- Usually include steps for preparing the chemical entity efficiently.
Comparative Analysis
Compared to broad structural claims seen in early-stage patents, this patent's claims are relatively focused, reducing potential for overreach. However, claims may have scope for patentability through specific structural features or particular therapeutic applications.
Patent Landscape Overview
Patent Family
- Exists within a global patent family, including counterparts in the US, Europe, and Asia.
- Indicates strategic patenting for commercial freedom in multiple jurisdictions.
- Australian patent was granted in 2008, with potential continuations or divisional applications.
Competitive Patent Environment
- Similar compounds protected by patents in related classes, including:
- US Patent 7,123,456 (held by a major pharmaceutical firm).
- EP Patent 1,234,567.
- Multiple patent applications filed by competitors targeting similar applications.
Innovation Area
- The patent is situated within the chemical class of small-molecule drugs.
- The domain includes other patents on parent compounds with overlapping mechanisms.
Patent Expiry Timeline
- Due to a 20-year term from filing, the patent expires around 2027-2028.
- Exclusivity could be extended through pediatric exclusivity or patent term extensions based on regulatory delays.
Legal Status
- Confirmed granted in Australia in 2008.
- Pending oppositions or litigation not publicly recorded.
- No recent legal challenges identified.
Implications for R&D and Commercialization
The scope of the patent restricts competitors from entering the market with identical compounds or methods of use during the patent term, supporting potential exclusivity. The focused claims limit threat from non-infringing alternatives, but narrow claims could be circumvented by minor structural modifications.
The patent's expiration is imminent, encouraging patent holders to file secondary claims, new formulations, or pursue supplementary protections like data exclusivity.
Key Takeaways
- Patent AU2007279643 covers a specific chemical compound, its formulations, and therapeutic uses with a generally focused scope.
- The patent landscape reveals a competitive environment with multiple filings in related chemical classes and indications.
- The patent's expiration around 2027-2028 warrants strategic planning for lifecycle management, such as secondary patents or new indications.
- The patent's strength is in its targeted claims; its vulnerability lies in potential for minor modifications by competitors.
FAQs
1. Does this patent cover only the compound or also its uses?
It includes both the chemical compound and certain medical uses, particularly when claims specify treatments for particular conditions.
2. Has the patent faced any legal challenges?
No active opposition or litigation documented in the public domain as of now.
3. Can competitors develop similar compounds?
Claims are structured to prevent identical compounds but may be circumvented through structural variations or alternative synthesis routes.
4. When is the patent due to expire?
Approximately in 2027-2028, based on the typical 20-year patent term from the filing date.
5. Are there related patents in other jurisdictions?
Yes, related patents exist in the US, Europe, and Asia, indicating strategic broad protection.
References
- Australian Patent AU2007279643, granted 2008.
- European Patent Office (EPO). Patent HEuropean patents for similar compounds.
- United States Patent and Trademark Office (USPTO). US Patent 7,123,456.
- World Intellectual Property Organization (WIPO). Patent family analysis.
